A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

This is a multicenter (study conducted at multiple sites), randomized (the study medication
is assigned by chance), double blind (neither investigator nor the participant knows the
treatment that the participant receives), placebo controlled (an inactive substance that is
compared with the study medication to test whether the study medication has a real effect in
clinical study), study to assess the efficacy and safety of CNTO 328 plus BSC compared with
BSC in patients with symptomatic Multicentric Castleman's Disease. The study mainly consists
of 3 phases, including: the screening phase (majority of assessments performed within 28 days
of first dose), the treatment phase (blinded and unblinded), and the follow up phase. In the
blinded treatment phase, approximately 78 patients will be randomly assigned in 1:2 ratios to
either of 2 treatment groups, ie, Placebo + BSC, or CNTO 328 + BSC. Participants receiving
placebo + BSC during blinded treatment period who do not respond and have treatment failure
will have the option to crossover and receive siltuximab + BSC during unbllinded treatent
period. The follow up phase will be 3 months after last dose of study medication and the
survival will be followed up until the study ends. Safety evaluations for adverse events,
clinical laboratory tests, electrocardiogram, vital signs, patient-recorded temperature, and
physical examination will be monitored throughout the study. The total study duration will be
5 years after the last patient starts study medication.

Inclusion Criteria:

- Measurable and symptomatic Multicentric Castleman's Disease

- Adequate organ function as assessed by laboratory values evaluated by the investigator
to determine eligibility prior to treatment

- Eastern Cooperative Oncology Group performance status of 0, 1, or 2

- Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone, and has remained
stable or decreased over the 4 weeks before treatment

Exclusion Criteria:

- Human Immunodeficiency Virus or Human Herpes Virus-8 positive

- Skin lesions as sole measurable manifestation of Multicentric Castleman's Disease

- Previous history of lymphoma

- Malignancies, except for adequately treated basal cell or squamous cell carcinoma of
the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which
the patient has been disease-free for 3 or more years

- Concurrent medical condition or disease that may interfere with study participation

- Prior exposure to Interleukin-6 or Interleukin-6 receptor targeted therapies